Home » Pozen, Teva Agree to Settlement in Treximet Patent Litigation
Pozen, Teva Agree to Settlement in Treximet Patent Litigation
Pozen and Teva Pharmaceuticals USA have
settled patent litigation over Teva’s ANDA for a generic version of migraine drug Treximet. Teva will
be dismissed without prejudice from consolidated litigation pending in the U.S. District Court for the Eastern District of Texas against Par Pharmaceutical,
Alphapharm and Dr. Reddy’s Laboratories, as well as Teva, according to Pozen.
Generic Line
Generic Line
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May